Stockreport

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma [Yahoo...

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF or refractory follicular lymphoma (FL) treated with tafasitamab (Monjuvi ® ) in combination with lenalidomide and rituximab Positive data featured in a late-breaking o [Read more]